A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach

Early in 2023, Takeda continued the company’s commitment to serving oncology patients by entering an exclusive licensing agreement with HUTCHMED (China) Limited for the commercialization of the metastatic colorectal cancer (mCRC) candidate fruquintinib (FRUZAQLA®) outside of mainland China, Hong Kong and Macau. In November 2023, the FDA approved FRUZAQLA® for adult patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. “The therapy is the first targeted one approved for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade,” Annette Montandon, Head of Sales, US Oncology, told BioSpace.